Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729596 · ClinicalTrials.gov registry record · Phase 1
MGC018 With or Without MGA012 in Advanced Solid Tumors
A Phase 1 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
NCT03729596 is a Phase 1 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 143 participants.
The verdict
NCT03729596, a Phase 1 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for permanent discontinuation may undergo additional cycles for up to two years. Patients in Cohort Expansion will be followed for survival every 3 months for 2 years following last dose.
Interventions
- BIOLOGICAL vobramitamab duocarmazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2023-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03729596
The ClinicalTrials.gov registry entry for NCT03729596 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vobramitamab duocarmazine is the first listed.
NCT03729596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03729596 about?
NCT03729596 is a clinical study titled "MGC018 With or Without MGA012 in Advanced Solid Tumors". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Coho...
What is the current status of trial NCT03729596?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2018-11-21. Estimated completion is 2023-03-18.
What interventions are being tested in trial NCT03729596?
The interventions under investigation include: vobramitamab duocarmazine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03729596?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.